NERV
vs
S&P 500
NERV
S&P 500
Over the past 12 months, NERV has significantly outperformed S&P 500, delivering a return of +91% compared to the S&P 500's +14% growth.
Stocks Performance
NERV vs S&P 500
Performance Gap
NERV vs S&P 500
Performance By Year
NERV vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Minerva Neurosciences Inc
Glance View
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2014-06-25. The firm is focused on the development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. The firm's lead product candidates are roluperidone (MIN-101), seltorexant and MIN-301. Roluperidone (MIN-101) is a compound that blocks serotonin, sigma, and α adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. The firm is developing roluperidone to treat patients with schizophrenia. Roluperidone is designed to block a specific subtype of serotonin receptor called 5-HT2A. The firm is developing seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD). MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson’s disease and for other neurodegenerative disorders.
